Dianthus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Dianthus Therapeutics's earnings have been declining at an average annual rate of -63.6%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 46.5% per year.
Key information
-63.6%
Earnings growth rate
98.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -46.5% |
| Return on equity | -13.5% |
| Net Margin | -1,557.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dianthus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3 | -50 | 21 | 40 |
| 31 Dec 23 | 3 | -44 | 18 | 33 |
| 30 Sep 23 | 4 | -43 | 16 | 34 |
| 30 Jun 23 | 4 | -36 | 9 | 33 |
| 31 Mar 23 | 6 | -31 | 8 | 30 |
| 31 Dec 22 | 6 | -28 | 7 | 29 |
| 31 Dec 21 | 1 | -13 | 2 | 13 |
Quality Earnings: DNTH is currently unprofitable.
Growing Profit Margin: DNTH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DNTH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DNTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: DNTH has a negative Return on Equity (-13.47%), as it is currently unprofitable.